tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Prelude Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports Q2 2025 Financial Results
2M ago
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
Premium
Company Announcements
Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
2M ago
Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
Premium
The Fly
Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
2M ago
Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
PremiumCompany AnnouncementsPrelude Therapeutics Advances Cancer Treatment with New Phase 2 Study
4M ago
Prelude Therapeutics Appoints Paul Scherer as Director
Premium
Company Announcements
Prelude Therapeutics Appoints Paul Scherer as Director
4M ago
Prelude Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Prelude Therapeutics Reports Q1 2025 Financial Results
6M ago
Prelude Therapeutics Reports 2024 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports 2024 Financial Results
8M ago
Prelude Therapeutics Reports 2024 Financial Results and Updates
Premium
Company Announcements
Prelude Therapeutics Reports 2024 Financial Results and Updates
8M ago
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
Premium
The Fly
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100